Glycophos (sodium glycerophosphate)

Where it stands

Glycophos (sodium glycerophosphate), from Fresenius Kabi USA, was approved by the US FDA on 2026-07-29 under NDA220381. The FDA milestone describes it as a new active ingredient in a solution dosage form. This is the only milestone in the records.

The records do not state the approved indication, the therapeutic area, the route of administration, the strength or the patient population. This analysis therefore cannot describe how the product is meant to be used. Check the FDA-approved labeling for those details.

Regulatory pathway and designations

The product was approved in the US through a New Drug Application (NDA220381). The records flag it as a "New active ingredient". In general terms, this means the FDA's classification treats the active component as not previously approved in an FDA-approved product. The records do not say which NDA subtype was used (for example, a full 505(b)(1) or a 505(b)(2) application), so no conclusion can be drawn on that point.

The records list no other designations, such as priority review, fast track, breakthrough therapy or orphan drug. They also give no PDUFA date or review timeline. No CHMP opinion date is listed, and the record is US-only, so there is nothing here on EU status. A CHMP opinion is part of the EU centralised procedure and does not apply to this FDA approval.

Safety and pharmacovigilance

The records contain no safety data. They include no warnings, contraindications, adverse-event information, risk management measures or postmarketing requirements. They do not say whether a REMS or postmarketing study commitments accompany the approval.

As general background, the NDA holder will be subject to standard US postmarketing safety reporting once the product is marketed. Safety information is set out in the approved prescribing information, which should be the reference for any product-specific risk assessment.

What to watch

The first step is to review the approved labeling and the FDA approval documents for the indication, dosing, warnings and any postmarketing commitments. The records do not provide these.

Other points to monitor are the product's US launch and availability, and any filings in other regions. The records give no information on any of these, so no timing or outcome can be inferred.